STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript

SA Transcripts158.79K FollowersFollow5ShareSaveCommentsQ4: 2026-03-03 Earnings SummaryPlay CallPlay CallPR10-KEPS of $0.01 misses by $0.16 | Revenue of $57.80M (18.08% Y/Y) misses by $17.25M STAAR Surgical Company (STAA) Q4 2025 Earnings Call March 3, 2026 5:30 PM EST Company Participants Connie JohnsonWarren Foust - Interim Co-CEO, President & COODeborah Andrews - Interim Co-CEO & CFO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research DivisionIseult McMahon - BTIG, LLC, Research DivisionBradley Bowers - Mizuho Securities USA LLC, Research DivisionGursimran Kaur - Wells Fargo Securities, LLC, Research DivisionJohn Young - Canaccord Genuity Corp., Research DivisionDavid Saxon - Needham & Company, LLC, Research DivisionMason Carrico - Stephens Inc., Research DivisionAdam Maeder - Piper Sandler & Co., Research Division Presentation Operator Good day, and welcome to the STAAR Surgical Company Fourth Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Connie Johnson, Director, Investor Relations. Please go ahead.

Connie Johnson Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, Interim Co-CEO, President and Chief Operating Officer of STAAR Surgical; and Deborah Andrews, Interim Co-CEO and Chief Financial Officer of STAAR Surgical. Earlier today, we reported our fourth quarter and fiscal 2025 results via press release and Form 8-K. We posted our results release and shareholder letter to our investor website at investors.staar.com. Today's call is scheduled for 1 hour and will include Q&A for publishing analysts. Webcast participants can also send questions for today's Q&A session to ir@staar.com. Before we get started, I want to remind you that during today's discussion, we will be making forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. I encourage you to read the disclaimers in today's release, the shareholder letter as well